Botox 200 unit vials
Ended Awarded Last action
- Contract number
- SPE2DR26FHGW8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,941
Award facts
- Contract value 100% obligated
- $19,941.12 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $19,941.12 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of BOTOX 200 Unit Vials. The award, issued on January 28, 2026, with an ultimate completion date of February 19, 2026, utilizes firm fixed-price pricing with no set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis despite its small business status. This delivery order is issued under the company's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that establishes multiple regional prime vendor contractors to supply pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group's selection under the PPV-G GEN V program reflects its demonstrated capability to fulfill specialized pharmaceutical requirements across diverse therapeutic categories for military medical operations. The company's established track record on numerous delivery orders ranging in value and its comprehensive product portfolio—encompassing branded and generic medications, biologics, vaccines, and specialty pharmaceuticals—positions it as a critical supplier within the federal military pharmaceutical supply chain. The indefinite delivery vehicle under which this award is issued extends through December 31, 2036, with a $499,999,999 ceiling value, enabling the DLA to issue additional firm fixed-price delivery orders as operational medical supply needs arise across global Department of Defense healthcare facilities.
Quick answers
Who was awarded contract SPE2DR26FHGW8?
SPE2DR26FHGW8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26FHGW8 worth?
The government has obligated $19,941 on SPE2DR26FHGW8.
Is contract SPE2DR26FHGW8 an order under another contract?
Yes. SPE2DR26FHGW8 is a delivery order under SPE2DR25D9244, an indefinite delivery contract.
Was contract SPE2DR26FHGW8 competed?
The extent of competition for SPE2DR26FHGW8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award